Overview
NICE is unable to make a recommendation on lenalidomide (Revlimid) for treating relapsed or refractory mantle cell lymphoma. This is because Celgene did not provide an evidence submission.
Last reviewed: 9 March 2022
Next review: We will review this decision if the company decides to make a submission.